Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Aug;31(8):1177–1182. doi: 10.1128/aac.31.8.1177

Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.

H C Standiford, G L Drusano, A Forrest, B Tatem, K Plaisance
PMCID: PMC174899  PMID: 3631942

Abstract

We compared ciprofloxacin (200 mg) with cefotaxime (2 g) when each was administered intravenously over a 30-min period to six volunteers in a crossover manner 1 week apart. To integrate the pharmacologic and microbiologic activity, inhibitory and bactericidal activities in serum were obtained for both antibiotics 1 and 6 h after administration against 10 strains of Escherichia coli, 10 strains of Klebsiella pneumoniae, 15 strains of Pseudomonas aeruginosa, and 10 strains each of methicillin-susceptible and -resistant Staphylococcus aureus. Geometric mean bactericidal titers for E. coli 1 h after the infusion were 1:60 for ciprofloxacin and 1:252 for cefotaxime, and for K. pneumoniae they were 1:20 and 1:256, respectively. However, geometric mean titers were poor for both antibiotics against methicillin-susceptible S. aureus (less than 1:2 for ciprofloxacin versus 1:5 for cefotaxime) and methicillin-resistant S. aureus (less than 1:2 for both antibiotics), as well as against P. aeruginosa (1:3 for ciprofloxacin versus 1:2 for cefotaxime). These data suggest that ciprofloxacin may be useful for the treatment of serious infections caused by E. coli and K. pneumoniae. However, caution is suggested when this dose of ciprofloxacin is used in situations in which septicemia is caused by P. aeruginosa or S. aureus and originates outside the urinary tract.

Full text

PDF
1177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge K. E., Janney A., Sanders C. V. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations. Antimicrob Agents Chemother. 1985 Nov;28(5):634–638. doi: 10.1128/aac.28.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boyce J. M., Causey W. A. Increasing occurrence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control. 1982 Sep-Oct;3(5):377–383. doi: 10.1017/s0195941700057337. [DOI] [PubMed] [Google Scholar]
  3. Chalkley L. J., Koornhof H. J. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985 Aug;28(2):331–342. doi: 10.1128/aac.28.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Johnson M., Miniter P., Andriole V. T. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis. J Infect Dis. 1987 Apr;155(4):783–788. doi: 10.1093/infdis/155.4.783. [DOI] [PubMed] [Google Scholar]
  7. LeBel M., Vallée F., Bergeron M. G. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother. 1986 Mar;29(3):501–505. doi: 10.1128/aac.29.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McCormick E. M., Echols R. M., Rosano T. G. Liquid chromatographic assay of ceftizoxime in sera of normal and uremic patients. Antimicrob Agents Chemother. 1984 Mar;25(3):336–338. doi: 10.1128/aac.25.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Murillo J., Standiford H. C., Tatem B. A., Caplan E. S., Calia F. M. Parenteral prophylaxis against enterococcal endocarditis. Am J Med Sci. 1979 Mar-Apr;277(2):195–200. doi: 10.1097/00000441-197903000-00008. [DOI] [PubMed] [Google Scholar]
  10. Oblinger M. J., Bowers J. T., Sande M. A., Mandell G. L. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S639–S649. doi: 10.1093/clinids/4.supplement_3.s639. [DOI] [PubMed] [Google Scholar]
  11. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  13. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  14. Smith C. R., Ambinder R., Lipsky J. J., Petty B. G., Israel E., Levitt R., Mellits E. D., Rocco L., Longstreth J., Lietman P. S. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Ann Intern Med. 1984 Oct;101(4):469–477. doi: 10.7326/0003-4819-101-4-469. [DOI] [PubMed] [Google Scholar]
  15. Standiford H. C., Drusano G. L., Bustamante C. I., Rivera G., Forrest A., Tatem B., Leslie J., Moody M. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother. 1986 Mar;29(3):412–417. doi: 10.1128/aac.29.3.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Standiford H. C., Drusano G. L., Fitzpatrick B., Tatem B., Schimpff S. C. Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin. Antimicrob Agents Chemother. 1984 Sep;26(3):339–342. doi: 10.1128/aac.26.3.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Standiford H. C., Tatem B. A. Technical aspects and clinical correlations of the serum bactericidal test. Eur J Clin Microbiol. 1986 Feb;5(1):79–87. doi: 10.1007/BF02013474. [DOI] [PubMed] [Google Scholar]
  18. Strunk R. W., Gratz J. C., Maserati R., Scheld W. M. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother. 1985 Sep;28(3):428–432. doi: 10.1128/aac.28.3.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thompson R. L., Cabezudo I., Wenzel R. P. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):309–317. doi: 10.7326/0003-4819-97-3-309. [DOI] [PubMed] [Google Scholar]
  20. Warren J. W., Miller E. H., Jr, Fitzpatrick B., DiFranco D. E., Caplan E. S., Tenney J. H., Anthony W. C. A randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli. Rev Infect Dis. 1983 Mar-Apr;5 (Suppl 1):S173–S180. doi: 10.1093/clinids/5.supplement_1.s173. [DOI] [PubMed] [Google Scholar]
  21. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES